A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects With Metastatic Prostate Cancer - Tabular View

Tracking Information
First Received Date ^ICMJE	March 3, 2003
Last Updated Date	October 20, 2009
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00055471 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
Official Title ^ICMJE
Brief Summary	The primary purpose of this study is to determine the safest dose of ZD4054 in men with prostate cancer
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Prostatic Neoplasms Metastases, Neoplasm
Intervention ^ICMJE	Drug: ZD4054
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Men 18 years & older Confirmed diagnosis of prostate cancer with bone metastases Exclusion Criteria: No more than 2 prior chemotherapy regimens No radiation, chemotherapy or bisphosphonates in the past 4 weeks
Gender	Male
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00055471
Responsible Party
Study ID Numbers ^ICMJE	4054IL/0004
Study Sponsor ^ICMJE	AstraZeneca
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	AstraZeneca
Verification Date	October 2009
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP